Pelthos Therapeutics restates Q1 2026 net loss to USD 25.07 million

Reuters2026/08/13 11:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pelthos filed a Form 10-Q/A on Aug. 13, 2026, restating unaudited first-quarter 2026 financial statements due to ASC 820 valuation errors.
Convertible debt at March 31, 2026 was restated to $39.12 million from $23.28 million, lifting total liabilities to $126.11 million.
Net loss for the quarter was restated to $25.07 million from $10.24 million; change in fair value of convertible debt swung to a $9.63 million loss.
Cash and cash equivalents at March 31, 2026 remained $31.98 million; the restatement had no impact on cash flows.
Management reported a material weakness in internal controls tied to Level 3 fair value measurements for convertible debt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001919246-26-000111), on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pelthos Therapeutics restates Q1 2026 net loss to USD 25.07 million

You may also like

Crypto prices